CK20 Positive Tumor: Merkel Cell Carcinoma Most Likely
A tumor that is CK20 positive (with CDC2/CDK1 positivity being less relevant to diagnosis) most likely represents Merkel Cell Carcinoma (MCC), and you should immediately confirm diagnosis with TTF-1 staining (which should be negative) and proceed with complete skin/lymph node examination, biopsy with full immunohistochemistry panel, and staging workup.
Diagnostic Approach
Primary Immunohistochemistry Pattern
The CK20 positivity is the critical diagnostic clue here. CK20 is positive in 75-100% of Merkel Cell Carcinomas and shows a characteristic paranuclear "dot-like" staining pattern 1. This immunophenotype is highly specific for MCC when combined with other markers.
Confirmatory Testing Required
To definitively diagnose MCC and exclude mimics, you must obtain:
- TTF-1 staining: Should be negative in MCC but positive in >80% of small cell lung cancer (SCLC), the main differential diagnosis 1
- Additional neuroendocrine markers: Chromogranin A, synaptophysin, CD56, NSE, or neurofilament protein to support the diagnosis 1
- CK7 staining: Typically negative or less prevalent in MCC (helps exclude SCLC which is CK7+ in >80% of cases) 1
Critical Differential Diagnoses
The CK20+/TTF-1- pattern effectively distinguishes MCC from:
- Small cell lung cancer: CK20 rarely positive, TTF-1 positive in >80% 1
- Colorectal adenocarcinoma: While CK20+ in 81% of cases, these show different morphology and are typically CK7-/CK20+ (65.8%) but lack neuroendocrine markers 2, 3
- Urothelial carcinoma: Can be CK20+, but clinical context and morphology differ 3
Immediate Next Steps
1. Pathology Confirmation
Have an experienced pathologist review the case to distinguish MCC from cutaneous simulants and metastatic tumors 1. The diagnosis should never rest on H&E alone.
2. Complete Initial Workup
- Thorough skin examination: Look for the primary cutaneous lesion
- Complete lymph node examination: Palpate all nodal basins
- Biopsy analysis with synoptic reporting including:
- Tumor size (maximum diameter, measured clinically before resection)
- Peripheral and deep margin status
- Lymphovascular invasion
- Extracutaneous extension (fascia, muscle, cartilage, bone)
- Tumor thickness (Breslow depth in mm)
- Mitotic rate
- Growth pattern (nodular vs infiltrative)
- Tumor-infiltrating lymphocytes 1
3. Staging Workup
Proceed with imaging for baseline staging:
- CT, MRI, or FDG-PET/CT to detect primary tumor extent, lymph node metastases, and distant metastases 1
Common Pitfalls to Avoid
- Do not rely on CK20 alone: Up to 25% of MCCs may be CK20 negative, requiring additional neuroendocrine markers for diagnosis 1
- Do not confuse with colorectal metastases: While both can be CK20+, MCC shows neuroendocrine markers and paranuclear dot-like CK20 pattern 1
- Do not measure tumor size only on fixed tissue: Clinical measurement before resection is required for accurate AJCC T-staging, as formalin fixation causes shrinkage 1
- CDC2/CDK1 positivity is not diagnostically useful here: While CDK1 overexpression has prognostic implications in colorectal cancer 4, it does not help differentiate tumor types and should not influence your diagnostic algorithm
The CK20+ immunophenotype with appropriate clinical context (cutaneous/subcutaneous location) and morphology strongly suggests MCC until proven otherwise 1.